Drug Topics
FEBRUARY 20, 2024
Drug Topics sat down with Jude Dieterman, CEO of Outcomes, to discuss the value and uniqueness of the company in the pharmacy market, what’s next on the horizon, and the upcoming event.
STAT
FEBRUARY 20, 2024
Groundbreaking research more than a decade ago showed that almost one-fifth of people enrolled in Medicare were being readmitted within 30 days after being discharged from the hospital, harming patients and increasing costs. That study led to a sea change in health care. The government started closely monitoring readmission rates and imposing fines on hospitals with high rates.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
FEBRUARY 20, 2024
Mental health challenges in the United States were exacerbated by the COVID-19 pandemic, and pharmacists are poised to help pick up the pieces.
STAT
FEBRUARY 20, 2024
Lynn Cole was in a never-ending cycle of getting recurrent blood infections. And no antibiotic drugs managed to kill off her zombie-like bacteria. “It just got so frustrating over the years because we couldn’t find the source, so we couldn’t figure out how to treat it and prevent it from happening,” said Mya Cole, Lynn’s daughter.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Fierce Pharma
FEBRUARY 20, 2024
After laying out plans to absorb a pair of production subsidiaries in October, Japan’s Daiichi Sankyo is doubling down on its quest to dominate the red-hot antibody-drug conjugate (ADC) field. | Aiming to beef up development and manufacturing of antibody-drug conjugates, Daiichi Sankyo is plugging roughly €1 billion ($1.08 billion) into an expansion of its production facility in Pfaffenhofen an der Ilm, Germany.
STAT
FEBRUARY 20, 2024
An increasing number of medical device companies are submitting fabricated and unreliable data, the Food and Drug Administration noted Tuesday morning. The data comes from third-party labs hired by device firms to test the quality of their products. Triple-check your data or we’ll reject your device, the FDA warned. The goal of third-party testing is to ensure a device meets the FDA’s standards in a range of areas, including biocompatibility, sterility, and mechanical performance.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
STAT
FEBRUARY 20, 2024
AbbVie announced Tuesday that CEO Richard Gonzalez, who has managed the company’s ascent since it was spun off from the device maker Abbott Laboratories in 2013, will step down in July. Gonzalez had previously said he would depart when AbbVie had a plan in place to move on from its best-selling drug, Humira , which is now facing competition from cheaper biosimilars.
Drug Topics
FEBRUARY 20, 2024
As pharmacies continue their rapid adoption of technological tools to improve efficiency, being prepared for cyberattacks is more important than ever.
STAT
FEBRUARY 20, 2024
WASHINGTON — Drugmakers are doing everything to tap the bottomless well of demand for new obesity drugs , and they might get some government help. The agency that regulates Obamacare insurance is considering a technical change that would require insurers to cover obesity drugs in a market of more than 20 million Americans. Weight loss drugs are a blessing for patients , a boon for drugmakers , and a potentially huge expense for insurers and taxpayers.
Drug Topics
FEBRUARY 20, 2024
The approval was based on positive data from a phase 3 trial that showed patients treated with omalizumab were significantly more likely to tolerate peanut, milk, egg, or cashew protein without moderate to severe allergic symptoms.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
STAT
FEBRUARY 20, 2024
The federal government’s plan to boost its oversight of the use of artificial intelligence tools in health care drew censure from startups arguing that overregulation stifles new ideas. But as Washington forges ahead, founders say they’re in the dark about who will be regulated and how — and they’re urging policymakers to offer clarity.
Fierce Healthcare
FEBRUARY 20, 2024
As the No Surprises Act took full effect, the number of in-network claims processes grew notably, according to a new analysis from FAIR Health. | As the No Surprises Act took full effect, the number of in-network claims processes grew notably, according to a new analysis from FAIR Health.
STAT
FEBRUARY 20, 2024
Ring Therapeutics, a gene therapy startup launched by Flagship Pioneering, has laid off just under 20% of its staff, or 19 employees, Flagship confirmed to STAT. The move comes as Sonata Therapeutics, another Flagship startup, has let go of a third of its staff , part of a broader hunkering down by platform companies. As funding for private biotechs remains scarce, startups hoping to develop new technologies — always an expensive, setback-ridden process — have had to make tough cho
Pharmacy Times
FEBRUARY 20, 2024
RSV can exacerbate asthma development by causing damage to the tissue in the airways, promoting inflammation and increasing airway hyper-responsiveness
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Fierce Healthcare
FEBRUARY 20, 2024
Siftwell Analytics, a company providing insights to community health plans to help improve member outcomes, has secured $5.8 million in the company's first venture capital funding round. | A digital health company built to help community plans utilize their data more efficiently raised nearly $6 million in a recent funding round.
Fierce Pharma
FEBRUARY 20, 2024
AstraZeneca, having surpassed its long-term $45 billion revenue goal last year, has handsomely rewarded its chief executive. | AstraZeneca CEO Pascal Soriot’s compensation package makes him the current top contender for 2023’s highest-paid pharma CEO in Europe. Still, as in years past, not everyone is pleased with Soriot’s 2023 windfall.
pharmaphorum
FEBRUARY 20, 2024
The FDA has said it plans to deliver a decision in June on the use of Argenx’ Vyvgart Hytrulo in rare autoimmune disease chronic inflammatory demyelinating polyneuropathy (CIDP).
Fierce Healthcare
FEBRUARY 20, 2024
Halfway through its 2024 fiscal year, Ascension has turned its operations around to the tune of about half a billion dollars. | The Catholic giant logged recurring operating margins of 3% for the quarter and 0.3% for the midway point of its current fiscal year.
Pharmacy Times
FEBRUARY 20, 2024
Datopotamab deruxtecan is an investigational TROP2 directed antibody drug conjugate that showed positive survival impact compared to chemotherapy.
pharmaphorum
FEBRUARY 20, 2024
The European Commission has approved Pfizer’s S1P receptor modulator Velsipity as a treatment for ulcerative colitis (UC), raising the pressure on Bristol-Myers Squibb’s first-to-market Zeposia.
Fierce Pharma
FEBRUARY 20, 2024
Since he took over as CEO at Bayer nine months ago, Bill Anderson had had to make tough decisions to try to get the floundering conglomerate back on track. | Bayer plans to cut its investor dividends to help reduce the company’s debt. Over three years, Bayer intends to pay out the legal minimum. For 2023, that comes to €0.11 per share compared to the €2.40 the company paid out per share in 2022.
Fierce Healthcare
FEBRUARY 20, 2024
MA governor orders Steward Health Care to disclose withheld financial documents, says it must exit state 'as soon as possible' dmuoio Tue, 02/20/2024 - 16:37
pharmaphorum
FEBRUARY 20, 2024
Patient feedback is driving innovation in next-generation drug delivery devices, improving patient adherence and experience. Learn how these advancements are shaping the future of healthcare.
Fierce Healthcare
FEBRUARY 20, 2024
Accountable care organizations are calling on the feds to increase participation of long-term and post-acute care providers in ACOs and to better incorporate episodic-based payments. | Payers, providers, ACO leaders and advocacy groups convened to discuss how to improve long-term and post-acute care participation in ACOs. These were their recommendations to CMS.
Fierce Pharma
FEBRUARY 20, 2024
On AbbVie’s latest earnings call, analysts were curious whether long-time CEO Richard Gonzalez was weighing a succession plan now that Humira’s loss of U.S. exclusivity has passed. | Robert Michael, AbbVie’s current president and chief operating officer, has been tapped by the company’s board of directors to take over Richard Gonzalez’s CEO post on July 1.
Fierce Healthcare
FEBRUARY 20, 2024
A year after hitting the pause button on a multi-billion-dollar health tech project at the Department of Veterans Affairs, federal lawmakers continue to have serious concerns about pharmacy softwar | A year after hitting the pause button on a multi-billion-dollar health tech project at the Department of Veterans Affairs, federal lawmakers continue to have serious concerns about pharmacy software issues that could impact patient safety.
STAT
FEBRUARY 20, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. The need-to-know this morning Rapt Therapeutics said the FDA placed a clinical hold on its anti-inflammation drug, called zelnecirnon, following a case of liver failure in one patient enrolled in a mid-stage atopic dermatitis study.
Fierce Healthcare
FEBRUARY 20, 2024
Community Health Systems (CHS)’ higher inpatient volumes and reimbursement rates couldn’t outpace rising costs, dragging the for-profit’s fourth-quarter earnings well below its performance in 2022. | The 71-hospital for-profit health system highlighted same-store volume growth but fell victim to higher supplemental reimbursement program costs, increased rates for outsourced medical specialists and other costs.
The Checkup by Singlecare
FEBRUARY 20, 2024
People with osteoarthritis or rheumatoid arthritis are sometimes prescribed a medication called meloxicam to manage symptoms of pain, swelling, and stiffness. Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) that treats some arthritis symptoms by blocking the prostaglandins , or chemicals, that cause pain and inflammation. However, many medications, supplements, and other substances—including caffeine— interact with meloxicam , leading some people to wonder if they can still consume t
pharmaphorum
FEBRUARY 20, 2024
Learn about the transparency of the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) regarding medicines pricing and the Association of the British Pharmaceutical Industry (ABPI). Explore how these factors impact the pharmaceutical industry.
PioneerRx
FEBRUARY 20, 2024
Many pharmacy trends have taken center stage over the last few years. The long-term care at-home model is rapidly gaining traction. Med sync is becoming less of.
pharmaphorum
FEBRUARY 20, 2024
In a new episode of the pharmaphorum podcast, host Nicole Raleigh speaks with Dr Brigham Hyde, co-founder and CEO of Atropos Health, and Ardy Arianpour, co-founder and CEO of SEQSTER, about their latest partnership, with its goal of personalised registries and the notion of the digital front door for patient information.
PharmaVoice
FEBRUARY 20, 2024
A significant growth is predicted for both AI and IoT in healthcare. By 2030, the AI market is expected to reach $187.95 billion USD, while the IoT market is projected to climb even higher to $312.7 billion USD.
The Checkup by Singlecare
FEBRUARY 20, 2024
Ibuprofen , commonly referred to by its brand names Advil and Motrin , is a nonsteroidal anti-inflammatory drug (NSAID) used to reduce pain and inflammation in the body. Although it may relieve pain symptoms faster, taking ibuprofen on an empty stomach may not be the safest option for everyone. NSAIDs can irritate the lining of the stomach and make existing gastrointestinal issues worse.
Expert insights. Personalized for you.
211 
Let's personalize your content